Genprex, Inc. Stock News

Genprex Senior Director of Quality Control & Product Development to Present Insights from Parallel AAV and Lipid-Based Development Programs Presentation to Highlight Drug Development, Manufacturing and Optimization Considerations for Diabetes Gene Therapy AUSTIN, Texas, Nov. 11, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology compan...

Whole-Blood Translational Analysis from Clinical Trial Patients Link TUSC2 to Mitochondrial Adaptation, Autophagy, and Protein Quality Control Expands Upon Existing REQORSA Research, Supporting Potential Beyond Oncology AUSTIN, Texas, Nov. 5, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed ...

Research to be Presented at the 2026 EORTC-NCI-AACR Symposium Links TROP2 Expression to Treatment Response and Explores its Role in Treatment Sensitivity Findings Suggest Low TROP2 Expression is Associated with Primary Resistance to REQORSA and May Help Guide Patient Selection AUSTIN, Texas, Nov. 4, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...

Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities with human brain Findings suggest that TUSC2 may play a foundational role in brain health AUSTIN, Texas, Oct. 21, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clin...

Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials AUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has entered int...

Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. 3, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, t...

Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that The Canadian Intellectual Property Office (C...

The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The World AUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its team will be attending and parti...